Related Experiment Video

Updated: May 10, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1

Y Iwagami1, H Eguchi, H Nagano

  • 1Department of Surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, Japan.

British Journal of Cancer
|June 27, 2013
PubMed
Abstract

Insights

MicroRNA-320c (miR-320c) drives gemcitabine resistance in pancreatic cancer by targeting SMARCC1. This miR-320c/SMARCC1 pathway may predict treatment response and offer a therapeutic target for pancreatic cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gemcitabine chemotherapy is standard for pancreatic cancer but faces resistance challenges.
  • Identifying mechanisms of gemcitabine resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To identify microRNAs (miRNAs) that regulate gemcitabine resistance in pancreatic cancer.
  • To investigate the role of miR-320c and its target gene SMARCC1 in pancreatic cancer chemoresistance.

Main Methods:

  • MicroRNA microarray analysis of gemcitabine-resistant and parental pancreatic cancer cell lines.
  • Gain/loss-of-function studies to assess miRNA effects on gemcitabine sensitivity.
  • In vitro and clinical sample analysis of the target gene SMARCC1.

Main Results:

  • miR-320c expression was elevated in gemcitabine-resistant cells.
  • miR-320c conferred gemcitabine resistance by targeting SMARCC1, a component of the SWI/SNF complex.
  • SMARCC1-positive patients showed improved survival after recurrence with gemcitabine therapy.

Conclusions:

  • miR-320c regulates gemcitabine resistance in pancreatic cancer via SMARCC1.
  • The miR-320c/SMARCC1 axis is a potential biomarker for predicting clinical response to gemcitabine.
  • Targeting miR-320c or SMARCC1 may offer a novel therapeutic strategy for pancreatic cancer.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...